|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM319759687 |
| 003 |
DE-627 |
| 005 |
20231225172131.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108662
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1065.xml
|
| 035 |
|
|
|a (DE-627)NLM319759687
|
| 035 |
|
|
|a (NLM)33412294
|
| 035 |
|
|
|a (PII)S1521-6616(20)30822-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a van Oers, Nicolai S C
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.02.2021
|
| 500 |
|
|
|a Date Revised 21.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a X-linked severe combined immunodeficiency (X-SCID) is a disorder of adaptive immunity caused by mutations in the IL-2 receptor common gamma chain gene resulting in deficiencies of T and natural killer cells, coupled with severe dysfunction in B cells. X-SCID is lethal without allogeneic stem cell transplant or gene therapy due to opportunistic infections. An infant with X-SCID became infected with SARS-CoV-2 while awaiting transplant. The patient developed severe hepatitis without the respiratory symptoms typical of COVID-19. He was treated with convalescent plasma, and thereafter was confirmed to have SARS-CoV-2 specific antibodies, as detected with a microfluidic antigen array. After resolution of the hepatitis, he received a haploidentical CD34 selected stem cell transplant, without conditioning, from his father who had recovered from COVID-19. SARS CoV-2 was detected via RT-PCR on nasopharyngeal swabs until 61 days post transplantation. He successfully engrafted donor T and NK cells, and continues to do well clinically
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Adaptive immunity
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Inborn errors of immunity
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
4 |
|a Severe combined immunodeficiency
|
| 700 |
1 |
|
|a Hanners, Natasha W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sue, Paul K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aquino, Victor
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Quan-Zhen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schoggins, John W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wysocki, Christian A
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 224(2021) vom: 04. März, Seite 108662
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:224
|g year:2021
|g day:04
|g month:03
|g pages:108662
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108662
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 224
|j 2021
|b 04
|c 03
|h 108662
|